Characteristics of initiators of budesonide/glycopyrrolate/formoterol for treatment of chronic obstructive pulmonary disease (COPD) in the United States: the AURA study.
Journal Information
Full Title: Ther Adv Respir Dis
Abbreviation: Ther Adv Respir Dis
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Pulmonary Medicine
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: ECP is a consultant for AstraZeneca. MP, LK, NF, and SP are employees of AstraZeneca and hold stocks/shares in AstraZeneca. IL, KS, XZ, and AN are employees of IQVIA, who received funding from AstraZeneca to conduct this study."
"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by AstraZeneca."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025